ASIT biotech: Information on the Total Number of Voting Rights and Shares
02 Mai 2019 - 05:45PM
Business Wire
Regulatory News:
ASIT biotech (BSE: ASIT) (Paris:ASIT) (ASIT -
BE0974289218), a clinical stage biopharmaceutical company
focused on the research, development and future commercialization
of breakthrough immunotherapy products for the treatment of
allergies, discloses the information required under article 15 of
the Belgian law of 2 May 2007 regarding the disclosure of important
shareholdings in listed companies.
Denominator – modified on 2 May 2019 following a capital
increase:
- New shares issued following the capital
increase: 125,131
- Total number of shares with voting
rights: 20,188,890
- Total number of voting rights
(=denominator): 20,188,890
Total number of shares with voting rights upon capital increase:
20,188,890
***
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical
company focused on the development and future commercialization of
a range of breakthrough immunotherapy products for the treatment of
allergies. Thanks to its innovative ASIT+™ technology platform,
ASIT biotech is currently the only developer of allergy
immunotherapy (AIT) product candidates consisting of a unique
mixture of highly purified natural allergen fragments in an optimal
size selection. This innovation results in a short treatment,
expected to improve patient compliance and real-life effectiveness.
ASIT biotech’s product pipeline contains three novel ASIT+™ product
candidates targeting respiratory allergies with the highest
prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III -
and house dust mite: hdm-ASIT+™), and food allergies (peanut
allergy: pnt-ASIT+™) that could significantly expand the current
immunotherapy market. The Company believes that its innovative
ASIT+™ platform is flexible and would be applicable across a range
of allergies.
ASIT biotech has a headcount of 26 staff members, at its
headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
Forward-looking statements
All statements in this announcement that do not relate to
historical facts and events are “forward-looking statements”. In
some cases, these forward-looking statements can be identified by
the use of forward-looking terminology, including the words
“believes,” “estimates,” “anticipates,” “expects,” “intends,”
“may,” “will,” “plans,” “continue,” “ongoing,” “potential,”
“predict,” “project,” “target,” “seek” or “should” or, in each
case, their negative or other variations or comparable terminology
or by discussions of strategies, plans, objectives, targets, goals,
future events or intentions. Forward-looking statements include
statements regarding the Company’s intentions, beliefs or current
expectations. By their nature, forward-looking statements involve
known and unknown risks and uncertainties because they relate to
events and depend on circumstances that may or may not occur in the
future. Forward-looking statements are not guarantees of future
performance. Given these risks and uncertainties, you should not
rely on forward-looking statements as a prediction of actual
results. Any forward-looking statements are made only as of the
date of this announcement and, without prejudice to the Company’s
obligations under applicable law in relation to disclosure and
ongoing information, the Company does not intend, and does not
assume any obligation, to update the forward-looking statements set
forth in this announcement.
Legal notice
This announcement does not constitute, or form part of, an offer
or invitation to sell or issue, or any solicitation of an offer to
purchase or subscribe for shares of ASIT biotech SA (the “Company”
and the “Shares”). Any purchase of, subscription for or application
for, Shares to be issued in connection with the intended offering
should only be made on the basis of information contained in the
prospectus and any supplements thereto, as the case may be. This
announcement does not constitute a prospectus and the information
contained herein is for information purposes only and does not
purport to be full or complete. Investors should not subscribe for
any Shares except on the basis of the information contained in the
prospectus that the Company expects to publish after its approval
by the Belgian Financial Services and Markets Authority, and which
can then be obtained at the Company’s registered office and on
www.asitbiotech.com
This announcement is not for distribution, directly or
indirectly, in or into the United States or to any U.S. person
within the meaning of the U.S. Securities Act of 1933, as amended
(the “Securities Act”). The Shares have not been and will not be
registered under the Securities Act and may not be offered or sold
in the United States, except pursuant to an exemption from the
registration requirements of the Securities Act. The Company has
not registered, and does not intend to register, any portion of the
intended offering of Shares in the United States, and does not
intend to conduct a public offering of Shares in the United
States.
This announcement and the information contained herein are not
for publication, distribution or release in or into the United
States, Australia, Canada, Japan or any jurisdiction where to do so
would constitute a violation of the relevant laws of such
jurisdiction.
The Company is responsible for the information contained in this
press release
THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,
AUSTRALIA, CANADA, JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD
BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE
IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190502005524/en/
CompanyMichel Baijot, CEOASIT biotechTel.: +32 2 264 03
90investors@asitbiotech.com
Media and Investor Relations - FranceNewCapDusan
Oresansky / Pierre LaurentTel.: +33 1 44 71 94
92asitbiotech@newcap.eu
Media Relations - BelgiumLaure-Eve MonfortTel.: +32 2 290
90 93monfort@comfi.be